$6.89 0.00 (0%)
12/3/2009 4:00 PM

Exelixis, Inc. (EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Member Avatar wolfhounds (23.43) Submitted: 10/2/2008 12:03:41 PM : Outperform Start Price: $5.67 EXEL Score: +21.49

As with any emerging Biotech, there a long wait for compounds to reach the market and the gamble that any will. But this company distinguishes itself by the number of compounds in development, the large pharma partners ponying up cash, and the science they have proven with the latest stage compounds. Patience should pay off with this stock.

Report this Post 1 Comment
Member Avatar wolfhounds (23.43) Submitted: 7/2/2009 9:29:25 AM
Recs: 0 Rec This

RL purchased avg cost 5.65

Report this Post

Featured Broker Partners